Dual IL-17A/F Blockade and Increased Candidiasis Risk

Dual inhibition of IL-17A and IL-17F impedes neutrophil chemotaxis, diminishing antifungal immunity.
In vitro data reveal increased survival of Candida in the presence of dual IL-17A/F blockade.
These findings help explain the higher rates of mucosal and systemic candidiasis in patients receiving bimekizumab.
Clinical vigilance and infection monitoring are warranted when prescribing dual IL-17A/F blockers, despite their efficacy in psoriatic arthritis.